Clinical Benefits Over Time Associated with Use of V-Go Wearable Insulin Delivery Device in Adult Patients with Diabetes: A Retrospective Analysis

摘要

Introduction Advances in insulin delivery have improved outcomes in patients with diabetes. This study evaluated the impact of V-Go_(?)Wearable Insulin Delivery device on glycated hemoglobin (A1C) and insulin total daily dose (TDD) in patients with diabetes not achieving glycemic targets. Methods Electronic medical record data was obtained for adult patients with A1C?>?7% treated at a multicenter endocrine practice who initiated V-Go between August 2012 and August 2015. Data were collected at baseline and for up to four follow-up visits, and were analyzed overall, stratified by insulin use at baseline, and for patients prescribed a basal-bolus insulin regimen delivered by multiple daily injections (MDI) at baseline. Economic evaluations were conducted in patients previously prescribed MDI regimens. Results Patients ( N ?=?103) were evaluated after a mean of 2, 6, 10, and 14?months of V-Go use. Baseline glycemic control was poor (A1C?>?9%) in 59% of patients. Significant, sustained reductions in A1C compared with baseline were observed at every visit ( p ?